<DOC>
	<DOCNO>NCT02737332</DOCNO>
	<brief_summary>The purpose study evaluate serum testosterone level patient Metastatic Castration-Resistant Prostate Cancer SoluMatrix™ Abiraterone Acetate Compared Abiraterone Acetate</brief_summary>
	<brief_title>A Study Evaluate Serum Testosterone Levels Patients With Metastatic Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description>This 12-week , open-label study abiraterone acetate least 50 patient metastatic castration-resistant prostate cancer . The primary endpoint total testosterone pharmacokinetic steady-state . Additional secondary endpoint include safety assessment , PSA pharmacokinetic measurement</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<criteria>1 . Written inform consent obtain prior studyrelated procedure perform 2 . Male subject least 18 year age old time consent 3 . Pathologically confirm adenocarcinoma prostate 4 . Ongoing therapy GnRH agonist antagonist AND serum testosterone level &lt; 50 ng/dL screen 5 . Metastatic disease document computed tomography ( CT ) / magnetic resonance imaging ( MRI ) bone scan . Imaging obtain within 42 day prior start study medication accept . 6 . Meeting disease progression accord recommendation prostate cancer work group 2 one follow criterion : Two rise PSA ( take minimum 1 week apart ) baseline measurement least 2 ng/mL , Imaging progression ( CT/MRI ) RECIST criterion Nuclear scan progression new lesion . 7 . Discontinuation flutamide nilutamide , antiandrogens least 4 week prior start study medication ; discontinuation bicalutamide least 6 week prior start study medication . 8 . Discontinuation Radiotherapy &gt; 4 week prior start study medication . 9 . ECOG performance status 01 screen 10 . Screening blood count follow : Absolute neutrophil count &gt; 1500/µL Platelets &gt; 100,000/µL Hemoglobin &gt; 9 g/dL 11 . Screening chemistry value follow : ALT AST &lt; 2.5 x ULN Total bilirubin &lt; 1.5 x ULN Creatinine &lt; 1.5 x ULN Albumin &gt; 3.0 g/dL 12 . Potassium &gt; 3.5 mmol/L 13 . Life expectancy least 6 month screen 14 . Subject willing able comply protocol requirement assessments 15 . Agrees protocoldefined use effective contraception . 1 . History impaired pituitary adrenal gland function 2 . Prior therapy abiraterone acetate , orteronel , ketoconazole CYP17 inhibitor 3 . Prior therapy enzalutamide 4 . Prior use experimental androgen receptor antagonist 5 . Previous exposure Ra223 : Xofigo 6 . Previous chemotherapy 7 . Initiation bisphosphonate denosumab therapy within 30 day prior start study medication . Patients stable dose medication least 30 day time start study drug eligible . 8 . Therapy estrogen within 30 day prior start study medication 9 . Use systemic glucocorticoid equivalent &gt; 10 mg prednisone daily ; patient discontinue reduce dose &lt; 10 mg prednisone within 14 day prior start study medication eligible 10 . Prior use herbal product may decrease PSA level ( eg. , saw palmetto ) within 30 day start study medication 11 . Known metastasis brain CNS involvement 12 . History malignancy within previous 2 year 13 . Major surgery within 30 day prior start study medication 14 . Blood transfusion within 30 day screen 15 . Serious , persistent infection within 14 day start study medication 16 . Persistent pain require use narcotic analgesic 17 . Known gastrointestinal disease condition may impair absorption 18 . Treatment investigational drug within 4 week prior Day 1 study . 19 . Known history human immunodeficiency virus ( HIV ) seropositive test hepatitis C virus hepatitis B virus 20 . Have poorly control diabetes . 21 . Uncontrolled hypertension 22 . History New York Heart Association ( NYHA ) class III IV heart failure 23 . Serious concurrent illness , include psychiatric illness , would interfere study participation 24 . Inability swallow tablet whole 25 . Known hypersensitivity excipients study medication 26 . Moderate severe hepatic impairment ( ChildPugh Classes B C )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>